Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2025-03-02 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
关于调整部分募集资金投入方式暨向全资子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of the use of raised funds and capital increase to a wholly-owned subsidiary. It details the board and supervisory meetings approving the capital increase, the use of funds, and the related approvals. The document is relatively short (3473 characters) and primarily serves as a formal announcement of a corporate financing and capital structure change. It does not contain comprehensive financial statements or detailed financial performance data. The content focuses on financing activities, specifically the adjustment of fundraising usage and capital injection into a subsidiary. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-03-02 Chinese
关于全资子公司拟签订《生物药物产业化项目（生物工程新药产业化项目）4
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the proposed signing of an EPC engineering contract by a wholly-owned subsidiary of the company. It details the contract parties, contract amount, approval status, contract content, and potential risks. The document is a formal disclosure about a significant contract but does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it an earnings release or audit report. It is also not a management or governance report. The document is a regulatory announcement about a capital project contract, which fits best under Capital/Financing Update (CAP) as it relates to a significant capital expenditure and project contract. The document length is 3349 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2025-03-02 Chinese
2024年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024 Annual Performance Express Report" and contains preliminary financial data for the year 2024, including revenue, net profit, earnings per share, and asset information. It explicitly states that the data is preliminary and unaudited, with final audited data to be disclosed in the formal 2024 Annual Report. The document is relatively short (1627 characters) and serves as an initial earnings summary or earnings release rather than a full annual report. It includes key financial highlights and a risk warning about the preliminary nature of the data. Therefore, this document fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2024
2025-02-23 Chinese
2024 年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast announcement by Beijing Northland Biotechnology Co., Ltd. It provides preliminary financial data for the full year 2024, including expected net profit loss, and explicitly states that the data is unaudited and subject to the final annual report. The document is short (730 characters) and serves as a forward-looking earnings preview rather than a full financial report. It is not the official Annual Report (10-K) but a performance forecast announcement. This type of document aligns best with an Earnings Release (ER) as it announces key financial results highlights for the year before the audited report is published. FY 2024
2025-01-23 Chinese
第六届董事会第十四次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the 6th Board of Directors of Beijing Northland Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, and voting results, specifically about purchasing minority shares of a subsidiary. There is no financial data or report content, but rather a corporate governance update about board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-01-12 Chinese
购买控股子公司少数股东股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the purchase of minority shareholder equity in a controlled subsidiary by the parent company. It details the transaction overview, parties involved, financial data of the subsidiary, pricing, agreement terms, and the impact on the company. It explicitly states that this transaction does not constitute a major asset restructuring and is not a related party transaction. The document is a formal announcement of a capital/financing activity involving equity acquisition to increase ownership from 92% to 100%. There are no indications that this is a full financial report, audit report, or regulatory filing unrelated to financing. The content fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising or capital structure changes through acquisition of shares in a subsidiary.
2025-01-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.